20(S)-Protopanaxadiol (PPD) analogues chemosensitize multidrug-resistant cancer cells to clinical anticancer drugs

Bioorganic and Medicinal Chemistry

Volumn 21, Issue 14, 2013, Pages 4279-4287

  Liu, Junhua ^a   Wang, Xu ^b   Liu, Peng ^a   Deng, Rongxin ^b   Lei, Min ^a   Chen, Wantao ^b   Hu, Lihong ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

20(S) Protopanoxadiol; Chemosensitizer; Multidrug resistant; P glycoprotein; Structure activity relationship

Indexed keywords

17 [2 HYDROXY 5 (ISOPROPYLAMINO)PENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [2 HYDROXY 5 (METHYL AMINO)PENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [2 HYDROXY 5 (PHENETHYLAMINO)PENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [2 HYDROXY 5 (PROPYLAMINO)PENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [2 HYDROXY 5 [(1 PHENYLETHYL)AMINO]PENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [2 HYDROXY 5 [(3 PHENYLPROPYL)AMINO]PENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [2 HYDROXY 5 [(4 METHOXYBENZYL)AMINO]PENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [2 HYDROXY 5 [(4 NITROPHENETHYL)AMINO]PENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [2 HYDROXY 5 [(PYRIDIN 2 YL METHYL)AMINO]PENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [2 HYDROXY 5 [(PYRIDIN 3 YL METHYL)AMINO]PENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [2 HYDROXY 5 [(PYRIDIN 4 YL METHYL)AMINO]PENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [2 HYDROXY 5 [3 (HYDROXYPROPYL)AMINO]PENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [2 HYDROXY 5 [4 (METHOXYPHENYL)AMINO]PENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [2 HYDROXY 5 [[2 (PIPERAZIN 1 YL)ETHYL]AMINO]PENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [5 (BENZYLAMINO) 2 HYDROXYPENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [5 (CYCLOPROPYLAMINO) 2 HYDROXYPENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [5 (ETHYLAMINO) 2 HYDROXYPENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [5 (TERT BUTYLAMINO) 2 HYDROXYPENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [5 [(3,4 DIMETHOXYBENZYL)AMINO]PENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [5 [(3,4 DIMETHOXYPHENETHYL)AMINO]PENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [5 [(4 CHLOROBENZYL)AMINO]PENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [5 [(4 CHLOROPHENETHYL)AMINO]PENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [5 [(4 FLUOROBENZYL)AMINO]PENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [5 [[2 (BENZO[D][1,3]DIOXOL 5 YL)ETHYL]AMINO] 2 HYDROXYPENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; 17 [5 [[3 (1H IMIDAZOL 1 YL)PROPYL]AMINO] 2 HYDROXYPENTAN 2 YL] 4,4,8,10,14 PENTAMETHYLHEXADECAHYDRO 1H CYCLOPENTA[A]PHENANTHRENE 3,12 DIOL; ANTINEOPLASTIC AGENT; PROTOPANAXADIOL; UNCLASSIFIED DRUG; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC 50; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; P-GLYCOPROTEIN; SAPOGENINS; TAXOIDS; VERAPAMIL;

EID: 84879030692     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2013.04.067     Document Type: Article

References (33)

1. R.C. Young Drug Resistance: The Clinical Problem R.F. Ozols, Drug Resistance in Cancer Therapy 1989 Kluwer Academic Press Boston 1 12
2. S.V. Ambudkar, S. Dey, C.A. Hrycyna, M. Ranmachandra, I. Pastan, and M.M. Gottesman Annu. Rev. Pharmacol. Toxicol. 39 1999 361
3. P.D.W. Eckford, and F.J. Sharom Chem. Rev. 108 2009 2989
4. M. Volm, and J. Mattern Crit. Rev. Oncog. 7 1996 227
5. A. Aszalos, and D.D. Ross Anticancer Res. 18 1998 2937
6. A.A. Hindenburg, M.A. Baker, E. Gleyzer, V.J. Stewart, N. Case, and R.N. Taub Cancer Res. 47 1987 1421
7. H. Thomas, and H. Coley Cancer Control 10 2003 159
8. G. Szakacs, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. Gottesman Nat. Rev. Drug Disc. 5 2006 219
9. R.W. Robey, S. Shukla, E.M. Finley, R.K. Oldham, D. Barnett, S.V. Ambudkar, T. Fojo, and S.E. Bates Biochem. Pharmacol. 75 2008 1302
10. H.Y. Hung, E. Ohkoshi, M. Goto, K.F. Bastow, K. Nakagawa-Goto, and K.H. Lee J. Med. Chem. 55 2012 5413
11. L.W. Qi, C.Z. Wang, and C.S. Yyan Nat. Prod. Rep. 28 2011 467
12. D. Zhang, T. Yasuda, Y. Yu, P. Zheng, T. Kawabata, Y. Ma, and S. Okada Free Radic. Biol. Med. 20 1996 145
13. J.Y. Shin, J.Y. Song, Y.S. Yun, H.O. Yang, D.K. Rhee, and S. Pyo Immunopharmacol. Immunotoxicol. 24 2002 469
14. L.C. Wang, and T.F. Lee Planta Med. 66 2000 144
15. S. Shibata J. Korean Med. Sci. 16 2001 28
16. H. Nishijo, T. Uwano, Y.M. Zhong, and T. Ono J. Pharmacol. Sci. 95 2004 145
17. S.W. Kim, H. Kwon, D.W. Chi, J.H. Shim, J.D. Park, Y.H. Lee, S. Pyo, and D.K. Rhee Biochem. Pharmacol. 63 2003 75
18. E.A. Bae, M.J. Han, M.K. Choo, S.Y. Park, and D.H. Kim Biol. Pharm. Bull. 25 2002 58
19. W. Jia, H. Yan, G. Bu, and Y. Zhao J. Clin. Oncol. 22 2004 63
20. H.C. Ren, J.G. Sun, G.J. Wang, H.T. Xie, W.B. Zha, B. Yan, F.Z. Sun, H.P. Hao, S.H. Gu, L.S. Sheng, F. Shao, J. Shi, and F. Zhou J. Pharm. Biomed. Anal. 48 2008 1476
21. M. Hao, Y. Zhao, P. Chen, H. Huang, H. Liu, H. Jiang, R. Zhang, and H. Wang PLoS ONE 3 2008 e2697
22. Y. Yu, Q. Zhou, Y. Hang, X.X. Bu, and W. Jia Cancer 109 2007 2374
23. Huang, D.; Qi, D. F. World Patent WO 2,003,024,459, 2003.
24. Winter, H. World Patent WO 2,005,040,189, 2005.
25. Huang, D. World Patent WO 2,003,103,682, 2003.
26. R. Kasai, K. Hara, R. Dokan, N. Suzuki, T. Mizutare, S. Yoshihara, and K. Yamasaki Chem. Pharm. Bull. 48 2000 1226
27. L. Li, X. Chen, D. Li, and D.F. Zhong Drug Metab. Dispos. 39 2011 472
28. I.K. Pajeva, and M. Wiese J. Med. Chem. 45 2002 5671
29. I.K. Pajeva, C. Globisch, and M. Wiese ChemMedChem 4 2009 1883
30. S.G. Aller, J. Yu, A. Ward, Y. Weng, S. Chittaboina, R. Zhuo, P.M. Harrell, Y.T. Trinh, Q. Zhang, I.L. Urbatsch, and G. Chang Science 323 2009 1718
31. Z. Bikadi, I. Hazai, D. Malik, K. Jemnitz, Z. Veres, P. Hari, Z. Ni, T.W. Loo, D.M. Clarke, E. Hazai, and Q. Mao PLoS ONE 6 10 2011 e25815
32. X. Wang, R. Deng, Y. Lu, Q. Xu, M. Yan, D. Ye, and W. Chen Basic Clin. Pharmacol. Toxicol. 112 1 2013 25
33. T. Nabekura, T. Yamaki, T. Hiroi, K. Ueno, and S. Kitagawa Pharmacol. Res. 61 2010 259